Acute Equol Supplementation and Vascular Function in Women With and Without CKD
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic
kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances
induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.
However, most of the literature in nephrology focuses on male patients, and studies on
women's vascular health are limited. Establishing effective therapies for improving vascular
function and reducing CVD risk in women with CKD is a high research priority of the NIH.
Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative
and anti-inflammatory properties. However, there is no information on the effect of equol on
vascular function in women with CKD. The goal of the proposed project is to determine the
acute effect (1 hour after ingestion) of oral equol supplementation on vascular function in
postmenopausal women with and without CKD.